Related Experiment Video

Updated: May 28, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

The ABCC4 gene is a promising target for pancreatic cancer therapy

Zhuo Zhang1, Jiancheng Wang, Baiyong Shen

  • 1Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China.

Gene
|October 13, 2011
PubMed

Insights

High ABCC4 protein levels drive pancreatic cancer growth. Inhibiting ABCC4 gene expression via short hairpin RNA (shRNA) significantly reduced pancreatic cancer cell proliferation and colony formation, suggesting ABCC4 as a therapeutic target for gene therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic cancer is a highly lethal malignancy with limited effective treatments.
  • Identifying novel therapeutic targets is crucial for improving patient outcomes.
  • ABCC4 protein is frequently overexpressed in pancreatic tumors.

Purpose of the Study:

  • To investigate the role of ABCC4 in pancreatic cancer proliferation.
  • To evaluate ABCC4 as a potential therapeutic target for pancreatic cancer gene therapy.

Main Methods:

  • Immunohistochemical assay to quantify ABCC4 protein in 36 pancreatic cancer specimens.
  • Lentiviral delivery of ABCC4 short hairpin RNA (shRNA) to downregulate ABCC4 expression in Panc-1 and BxPC-3 cells.
  • Assessment of cell proliferation, colony formation, and cell cycle progression.

Main Results:

  • High ABCC4 protein expression was observed in pancreatic cancer specimens.
  • Downregulation of ABCC4 using shRNA significantly inhibited proliferation and colony formation in vitro.
  • ABCC4 downregulation led to G1 phase cell cycle arrest.

Conclusions:

  • ABCC4 gene expression promotes pancreatic cancer cell growth.
  • Targeting ABCC4 represents a promising strategy for pancreatic cancer gene therapy.

More Related Videos

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...